<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A prothrombotic and hemorrhagic state can separately manifest in one patient and can potentially cause several diagnostic problems </plain></SENT>
<SENT sid="1" pm="."><plain>We report an intriguing case as an example of a potential hemostasis-based diagnostic dilemma </plain></SENT>
<SENT sid="2" pm="."><plain>A 29-year-old female patient presented with a personal history of <z:hpo ids='HP_0000132'>menorrhagia</z:hpo> and other mucosal <z:mp ids='MP_0001914'>bleeding</z:mp> and renal ovarian <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Previous investigations had uncovered several diagnostic anomalies, including <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand disease</z:e> (VWD), factor V Leiden (FVL), <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, and <z:e sem="disease" ids="C0040034" disease_type="Disease or Syndrome" abbrv="">thrombocytopaenia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Previous therapy in this patient included <z:chebi fb="5" ids="28304">heparin</z:chebi> and <z:chebi fb="8" ids="10033">warfarin</z:chebi> for the <z:mp ids='MP_0005048'>thrombosis</z:mp> and desmopressin <z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (DDAVP) and antifibrinolytic therapy for surgical management </plain></SENT>
<SENT sid="5" pm="."><plain>Subsequent laboratory testing with fresh samples consistently confirmed an equivocal (borderline <z:mpath ids='MPATH_458'>normal</z:mpath>/abnormal) level of <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (VWF) and FVL with activated protein C resistance (APCR) </plain></SENT>
<SENT sid="6" pm="."><plain>A patient sample, differentially labeled according to the tests being performed, was later distributed for blind testing to participants within several modules of the RCPA Quality Assurance Program (QAP) </plain></SENT>
<SENT sid="7" pm="."><plain>Most participants reported a low level of VWF consistent with possible mild Type 1 VWD, and most (but not <z:hpo ids='HP_0000001'>all</z:hpo>) reported a positive finding for APCR </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> participants correctly reported the sample as heterozygous for the FVL mutation, negative for the Prothrombin gene mutation G20210A, and heterozygous for the <z:chebi fb="0" ids="25297">methylenetetrahydrofolate</z:chebi> reductase (MTHFR) mutation C677T </plain></SENT>
<SENT sid="9" pm="."><plain>Interestingly, a significant number of laboratories performing Protein S testing using clot-based procedures also identified a false <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">Protein S deficiency</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, this exercise showed how, either depending on the clinical review and specific laboratory investigation and tests performed, a pro-<z:mp ids='MP_0001914'>bleeding</z:mp> diagnosis (of either VWD or <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>) or pro-<z:hpo ids='HP_0100724'>thrombophilia</z:hpo> risk (<z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid Syndrome</z:e> or FVL/APCR or false <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">Protein S deficiency</z:e>) could potentially and differentially arise in the one patient </plain></SENT>
</text></document>